This study from the NCC group, Korea, reported the results of 59 patients with inoperable extrahepatic cholangiocarcinoma (EHCC) treated with PBT to a median total dose of 50 GyRBE in 10 fractions, in combination with pre-PBT, or post-PBT chemotherapy, or no chemotherapy. The median OS times for the groups receiving no chemo, pre-PBT chemo, and post-PBT chemo were 14.6, 18.2, and 21.8 months, respectively (p<0.05 for each).

For the whole group, the 1-year and 2-year free from local progression (FFLP) rates were 86.1% and 66.4%, with a median time of FFLP of 30.9 months. There was ≥ grade 3 acute adverse events in 1.6% of the cases. The authors concluded that hypofractionated PBT for inoperable EHCC has demonstrated promising FFLP and OS rates with a safe toxicity profile.